دواعي استعمال ريميكاد 100مجم فيال 10 مل للتسريب الوريدي

Infliximab 100 mg lyophilized powder vial for intravenous infusion (reconstitute with 10 ml), single vial, Janssen, marketed in Egypt.

• Crohn disease (adults and pediatric patients >=6 years), including fistulizing diseaseDailyMed (U.S. National Library of Medicine)
• Ulcerative colitis (adults and pediatric patients >=6 years)DailyMed (U.S. National Library of Medicine)
• Rheumatoid arthritis (with methotrexate), ankylosing spondylitis, psoriatic arthritis and chronic severe plaque psoriasis (adults)DailyMed (U.S. National Library of Medicine)

• Most common (>10%): infections (e.g. upper respiratory, sinusitis, pharyngitis), infusion-related reactions, headache and abdominal pain.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)

• Doses >5 mg/kg in patients with moderate or severe heart failure.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
• Previous severe hypersensitivity reaction to infliximab, any inactive ingredient, or murine proteins.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)

• Boxed warning: serious infections (including tuberculosis, bacterial sepsis, invasive fungal and opportunistic infections) and malignancy, including lymphoma and fatal hepatosplenic T-cell lymphoma; test for latent TB before starting.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
• Hepatitis B reactivation, hepatotoxicity, heart failure, cytopenias, hypersensitivity/infusion reactions, demyelinating disease; live vaccines should not be given during treatment.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)

• Other biological products (e.g. anakinra, abatacept, tocilizumab)Combination not recommended: increased risk of serious infections.DailyMed (U.S. National Library of Medicine)
• Live vaccines / therapeutic infectious agentsShould not be given with REMICADE; wait at least 6 months after birth before live vaccines in infants exposed in utero.DailyMed (U.S. National Library of Medicine)

• Observational studies showed no increased risk of major malformations versus non-biologic exposure; infliximab crosses the placenta in the third trimester and may affect the infant immune response.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
• Infliximab is present at low levels in human milk; infant systemic exposure is expected to be low.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)

• Test for latent TB and hepatitis B before starting; monitor for active TB and infections during treatment.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)